Get the Stockscreener App
1.76
1.73%
0.03
After Hours:
1.79
0.03
+1.70%
Annovis Bio Inc stock is traded at $1.76, with a volume of 987.64K.
It is up +1.73% in the last 24 hours and down -30.16% over the past month.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
See More
Previous Close:
$1.73
Open:
$1.77
24h Volume:
987.64K
Relative Volume:
1.53
Market Cap:
$51.51M
Revenue:
-
Net Income/Loss:
$-28.85M
P/E Ratio:
-1.2553
EPS:
-1.4021
Net Cash Flow:
$-25.62M
1W Performance:
-23.48%
1M Performance:
-30.16%
6M Performance:
-2.76%
1Y Performance:
+44.26%
1-Day Range:
$1.70
$1.795
1-Week Range:
$1.5407
$1.98
52-Week Range:
$1.19
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio Inc
Sector
Industry
Phone
484-875-3192
Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
1.76 | 50.64M | 0 | -28.85M | -25.62M | -1.4021 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-25-24 | Upgrade | Maxim Group | Hold → Buy |
| Dec-29-23 | Initiated | Canaccord Genuity | Buy |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
Annovis Bio Inc Stock (ANVS) Latest News
Annovis Bio Price Target Maintained With a $17.00/Share by Canaccord Genuity - Moomoo
Aug Summary: Will Annovis Bio Inc stock recover after earnings2026 Chart Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn
Malvern company closes $10M offering to extend Alzheimer’s therapy testing - Pennsylvania Business Report -
Fed Watch: Can Annovis Bio Inc disrupt its industry2026 Spike Watch & Safe Capital Preservation Plans - baoquankhu1.vn
Retail Trends: Will Annovis Bio Inc benefit from seasonalityPortfolio Growth Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Annovis Bio highlights buntanetap development in published article - MSN
Annovis secures financing for buntanetap’s NDA submission - The Pharma Letter
Annovis Bio raises $10M to fund Alzheimer’s drug trial - Investing.com
Annovis Bio raises $10M to fund Alzheimer’s drug trial By Investing.com - Investing.com UK
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission - ChartMill
Annovis Bio Announces $10 Million Underwritten Offering to Advance Alzheimer’s and Parkinson’s Drug Development - Minichart
Annovis Bio Prices Registered Direct Offering to Fund Trials - TipRanks
Annovis Bio (ANVS) price target increased by 13.94% to 15.98 - MSN
Annovis Bio Secures ~$10 Million Underwritten Registered Direct Offering With Canaccord Genuity - TradingView — Track All Markets
Weekly Trades: Will Annovis Bio Inc. benefit from rising consumer demand2026 Market Trends & Safe Capital Preservation Plans - baoquankhu1.vn
Quarterly Risk: Will Annovis Bio Inc stock hit new highs in YEAR2026 Growth vs Value & Weekly Breakout Watchlists - baoquankhu1.vn
Annovis Bio prices $10M stock offering at $1.90 per share - Investing.com Australia
Annovis Bio (ANVS) launches $10M stock and warrant offering for Phase 3 drug - Stock Titan
Annovis Bio (ANVS) raises ~$10M via 5.26M-share registered direct offering - Stock Titan
Form 424B5 Annovis Bio, Inc. - StreetInsider
Annovis Bio stock tumbles 26% on dilutive equity offering By Investing.com - Investing.com India
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Annovis Bio stock tumbles 26% on dilutive equity offering - Investing.com
Anovis Bio Inc stock: $10M raise amid Phase 3 push – what it means for you - AD HOC NEWS
Annovis announces $10 million underwritten offering of common stock and accompanying warrants - marketscreener.com
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants - The Manila Times
ANVS Earnings History & Surprises | EPS & Revenue Results | ANNOVIS BIO (NYSE:ANVS) - ChartMill
Annovis Secures U.S. Patent for Buntanetap Neurological Use - MyChesCo
Annovis Bio Highlights Buntanetap Development in Published Article - MyChesCo
Will Annovis Bio Inc benefit from government policyEarnings Trend Report & Low Risk High Win Rate Picks - baoquankhu1.vn
Options Flow: Can Annovis Bio Inc deliver consistent dividendsChart Signals & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Growth Value: Whats the analyst consensus on Annovis Bio IncMarket Movers & Verified Chart Pattern Signals - baoquankhu1.vn
Annovis Strengthens Patent Portfolio With Buntanetap, Stock Up - RTTNews
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
ANVS.N Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Insider Buying: Annovis Bio (NYSE:ANVS) Director Acquires 713,800 Shares of Stock - MarketBeat
Annovis Bio Director Purchased Shares Worth Over $1.4M - TradingView — Track All Markets
Director Michael Hoffman buys 713,800 Annovis Bio (ANVS) shares in open market - Stock Titan
Annovis Bio receives patent for buntanetap in brain infections By Investing.com - Investing.com Australia
[144] Annovis Bio, Inc. SEC Filing - Stock Titan
Annovis Bio, Inc. Secures Patent for Buntanetap in Prevention and Treatment of Neurological Injuries from Infectious Agents - Quiver Quantitative
Annovis Bio receives patent for buntanetap in brain infections - Investing.com
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections - The Manila Times
Annovis Secures U.S. Patent for Buntanetap in the - GlobeNewswire
ANVS Stock Price and Chart — NYSE:ANVS - TradingView
ANVS.N PE Ratio & Valuation, Is ANVS.N Overvalued - Intellectia AI
Annovis Publishes Historical Review of Buntanetap in The Scientist - Bitget
Bearish Setup: Will Annovis Bio Inc stock hit new highs in YEAR2026 Technicals & Growth-Oriented Investment Plans - baoquankhu1.vn
Annovis Bio Inc Stock (ANVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):